Multiple Myeloma : News
Print
Email
SaveHealthline's Premium Tools
Healthline Part D Plan Selector
Medicare's drug plans are subsidized by the US federal government and offered through insurers.
Advertisement
Marketplace
|
... data emerging from a clinical trial of romidepsin in combination with Velcade (bortezomib) and dexamethasone in multiple myeloma will be presented later at the meeting. In an oral presentation entitled Clinically Significant Responses Achieved with ...
|
|
... States, Canada, Argentina and Switzerland in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy and in Australia in combination with dexamethasone for the treatment of ...
|
|
... environment that nurtures them. The U.S. Food and Drug Administration has approved the drug for treatment of multiple myeloma and some forms of myelodysplastic syndrome. The clinical trial is funded by Celgene. Co-authors with Ferrajoli are Susan ...
|
|
... States, Canada, Argentina and Switzerland in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy and in Australia in combination with dexamethasone for the treatment of ...
|
|
... SGEN) today reported data from a phase I clinical trial of SGN-35, an antibody-drug conjugate (ADC), demonstrating multiple complete and partial responses at well-tolerated doses in patients with relapsed or refractory Hodgkin lymphoma and other ...
|
|
... Center, 2266 Torrance Blvd., Suite 1, Torrance, 7 to 9 p.m. Tuesday. Call 310-422-9058 today to reserve a space. Multiple Sclerosis Harbor/South Bay Multiple Sclerosis support group meeting. The Neighborhood Center, McMasters Park, 3612 Artesia ...
|
|
... States, Canada, Argentina and Switzerland in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy and in Australia in combination with dexamethasone for the treatment of ...
|
|
... study of VELCADE, dexamethasone, cyclophosphamide and lenalidomide (VcDCR) in patients with previously untreated multiple myeloma (MM). The preliminary analysis of the safety data showed that the combination of four drugs was generally well ...
|
|
DEAR DR. DONOHUE: What can you tell me about multiple myeloma? I was told it was in my bone marrow and my skull.
|
|
... Mestman's prostate cancer went into remission, but then something else happened. Last year he was diagnosed with multiple myeloma, a type of worse, they had just lost their daughter to brain cancer that same year in March. 'That was probably the ...
|
|
... to better understand gene function. Also covered in the GEN article is research taking place at Eli Lilly, the Multiple Myeloma Research Foundation, Semafore Pharmaceuticals, Calistoga Pharmaceuticals, and Harvard Medical School. ...
|
|
... at 1:00 a.m. Last Modified: Friday, December 5, 2008 at 10:40 a.m. Dear Dr. Donohue: What can you tell me about multiple myeloma? I was told it was in my bone marrow and my skull. As of now, it is not in my brain. Will it go to the brain? My ...
|
|
... to better understand gene function. Also covered in the GEN article is research taking place at Eli Lilly, the Multiple Myeloma Research Foundation, Semafore Pharmaceuticals, Calistoga Pharmaceuticals, and Harvard Medical School. ...
|
|
... ongoing work with experts in the fields of oncology and hematology continue to provide valuable new insights across multiple cancer types." The most significant presentations at ASH include: -- Tasigna data showing its benefit in the first-line ...
|
|
... Inventory, and Beck Depression Inventory. Data analysis included descriptive statistics, correlations, and stepwise multiple regression. All participants had stomatitis; 47% had oral pain, with a subset reporting continuous moderate to severe oral ...
|
|
... at $52.60. CELG's Revlimid's (non-Hodgkin's lymphoma treatment) incremental Phase 3 data on Revlimid in first line multiple myeloma is expected at the American Society of Hematology (ASH) meeting on December 6 to December 9. CELG December option ...
|
|
... are welcome to attend an event to benefit Hallisey and his family. In the fall, Hallisey was diagnosed with multiple myeloma, a cancer of the blood. Hearing the life-altering news from the doctor left the 47-year-old Amesbury man with questions and ...
|
|
... changed in 38 percent of cases, ranging from 31.4 percent for non-melanoma skin cancer to 48.7 percent for myeloma, when the intended management was categorized as treatment or non-treatment. PET had a consistently greater impact on intended ...
|
|
DEAR DR. DONOHUE: What can you tell me about multiple myeloma? I was told it was in my bone marrow and my skull.
|
 |
 |
Home | About | Health Experts | Careers | Site Map | Feedback | Help | Health Tools | Tell a Friend
Advertise | Terms of Use | Privacy Policy
Advertise | Terms of Use | Privacy Policy
Copyright © 2005 - 2008 Healthline Networks, Inc. All rights reserved.